Navigation Links
In Light of Alleged Deceptive Marketing Claims Made by Drug Makers, Parker Waichman LLP Addresses Issues Allegedly Related to the Safety and Effectiveness of Plavix
Date:4/23/2013

New York, New York (PRWEB) April 23, 2013

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, is addressing safety concerns and other issues related to Plavix in light of a Wall Street Journal* article published on April 22, 2013. The article reviews several drugs that are at the center of deceptive marketing lawsuits filed by state authorities; the drugs include Johnson & Johnson’s Risperdal, GlaxoSmithKline’s Avandia and Sanofi Aventis, and Bristol-Myers Squibb’s Plavix. The attorneys general of West Virginia and Mississippi have taken action against makers of Plavix, alleging, among other things, that they made false and misleading claims about the superiority of the blood thinner compared to Aspirin.

“For years, there has been mounting evidence suggesting that Plavix manufacturers put patients at risk by failing to properly warn about this drug,” said Daniel C. Burke, Senior Litigation Counsel at Parker Waichman LLP. “These legal actions help support those suspicions. Our firm continues to receive inquiries from Plavix users who allege that the medication caused injuries such as gastrointestinal and cerebral hemorrhaging.” The national personal injury firm has filed a number of lawsuits on behalf of Plavix patients. One case, for example, was filed on behalf of a Georgia man on Sept. 28, 2012, in the Supreme Court of the State of New York, County of New York (Index No. 156776/2012).

West Virginia and Mississippi allege that Plavix makers made deceptive marketing claims by stating that Plavix is superior to Aspirin, the Journal reports. Both states also allege that the companies should have known that Plavix may not be properly metabolized in a certain subgroup of patients.

Last month, Sanofi, in a filing** with the U.S. Securities and Exchange Commission noted that it was being investigated by the U.S. Department of Justice over disclosures it made about Plavix. The company stated in the filing that it learned about the probe in June 2012.

Research has suggested that use of Plavix may not be more effective than Aspirin. One study, published last August in the New England Journal of Medicine***, found that combination or “dual therapy” with Aspirin and Plavix does not significantly reduce the risk of a second stroke compared to Aspirin by itself. The study also found that adding Plavix to Aspirin therapy increased the risk of bleeding and death.

** http://www.sec.gov/Archives/edgar/data/1121404/000104746913002333/a2212980z20-f.htm
*** http://www.nejm.org/doi/full/10.1056/NEJMoa1204133

If you or a loved one experienced serious, life-threatening internal bleeding, heart attacks, strokes, or a blood disorder, and you believe Plavix is to blame, please contact their office by visiting the firm's Plavix side effects page at yourlawyer.com. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).

Contact:
Parker Waichman LLP
Gary Falkowitz, Managing Attorney
(800) LAW-INFO
(800) 529-4636
http://www.yourlawyer.com

Read the full story at http://www.prweb.com/releases/plavix-lawsuits/04/prweb10664222.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Soothe High Anxiety with Deva Premal & Miten’s 21-Day Mantra Meditation Journey, Launching this Tuesday, April 23rd in Tandem with Their New Album, A Deeper Light
2. Left Coast Sports Innovation Launches New Website To Highlight The New “Grip and Assist” Mobility Gait Belt
3. No Tie Between Light Drinking During Pregnancy, Childs Development: Study
4. Some Slightly Obese May Gain From Weight-Loss Surgery, Guidelines Say
5. Babies Born Even Slightly Early May Lag Behind: Study
6. Solatube International Celebrates Earth Day 2013 by Harnessing the Sun’s Rays with Daylighting
7. Research sheds new light on traumatic brain injuries
8. Teens Death From Chickenpox Highlights Need for Vaccination, CDC Reports
9. Transparent Mouse Brain Could Shed Light on Human Brain Health
10. Noltensmeyer Insurance Services, LLC Encourages Parents to Talk to Teens about Distracted Driving In Light of a Recent Fatal Accident
11. Gene Kranz Highlight of STAR Global Conference 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... ... Dr. Jessica Barron, of Barron Family Dental in Thornton, Colorado , is ... the North Metro Denver area. The new dental practice focuses on comfort where patients ... the most relaxing environment. , While some dental visits can create anxiety for patients, ...
(Date:2/10/2016)... ... 2016 , ... United Benefit Advisors (UBA), the nation’s leading ... its growing list of Partner Firms. S.S. Nesbitt is headquartered in Birmingham, ... and in between. , Harnessing the experience and insights of the agency’s team ...
(Date:2/10/2016)... ... February 10, 2016 , ... Armune BioScience signed a definitive agreement ... laboratory service centers across the country. Launched in April of 2015, Apifiny is the ... prostate cancer. Apifiny order volume exceeded 3,000 tests in 2015. Primary care physicians and ...
(Date:2/10/2016)... ... 2016 , ... For additional information contact Phyllis Strupp 480-488-5858 , Brain improves ... The Ultimate Guide to Brain Training" by award-winning author Phyllis Strupp explains ... is March 16, 2016. A free review copy is available to the media ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... Everseat digital self-scheduling readily available to physicians. The integration will enable ... find and select appointments via Everseat’s free mobile app. , The partnership gives ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... ATLANTA , Feb. 10, 2016  LexisNexis® ... and technology, today announced the launch of ... analytics solution that helps improve and optimize the ... evaluation of performance using severity-adjusted scores. By measuring ... a critical solution to deliver better outcomes, improve ...
(Date:2/10/2016)... , Feb. 10, 2016 Mast ... developing novel, clinical-stage therapies for sickle cell disease and ... public offering of 29,090,910 units at a price to ... of one share of the Company,s common stock and ... common stock at an exercise price of $0.42 per ...
(Date:2/10/2016)... , Feb. 10, 2016 ALSP, Inc. announced ... MD as Consultant for Medical Affairs in preparation for its ... Michael Pierschbacher , PhD, CEO, stated, "We are pleased to ... look forward to working with an individual of such practical ... look forward to drawing deeply on his broad experience and ...
Breaking Medicine Technology: